(News Bulletin 247) – Bristol Myers Squibb yesterday announced the results of a Phase 2 study evaluating BMS-986278, a potentially first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis.

The study showed that BMS-986278 60 mg twice daily for 26 weeks reduced the rate of decline in percent predicted forced vital capacity (ppFVC) by 62% compared to placebo.

BMS-986278 was well tolerated, with adverse event and discontinuation rates comparable to placebo.

Pulmonary fibrosis is a devastating, life-threatening disease with daily symptoms including coughing, labored breathing and extreme fatigue.

“These data represent an important advance for patients and physicians, who eagerly await a new standard of care capable of mitigating lung function decline,” said Tamera J. Corte, clinical trial investigator, physician Respiratory and Director of Interstitial Lung Disease at the Royal Prince Alfred Hospital.

Copyright (c) 2023 News Bulletin 247. All rights reserved.